• Vaccine Name: E. coli O157:H7 subunit vaccine expressing Esps and Tir
• Target Pathogen: Escherichia coli
• Target Disease: Hemorrhagic colitis
• Vaccine Ontology ID: VO_0000459
• Type: Subunit vaccine
• Antigen: The antigen for this vaccine is supernatant proteins (containing Type III proteins Esps and Tir) prepared from E. Coli O157-H7 (Potter et al., 2004).
• Tir gene engineering:
  • Type: Protein purification
  • Description: The E. coli strain O157:H7 was used for the production of Type III secreted proteins Tir and Esps (Potter et al., 2004).
  • Detailed Gene Information: Click Here.
• Adjuvant: VSA-3 vaccine adjuvant
  • Adjuvant name: VSA-3 vaccine adjuvant
  • VO adjuvant ID: VO_0001266
  • Description: The adjuvant used was VSA3(Potter et al., 2004)
• Preparation: Supernatent proteins from E. coli O157-H7 were combined with the VSA3 to form protein concentrations of either 25 or 100 micrograms/ml. Each dose was 50 micrograms/ml (Potter et al., 2004).
• Virulence: Not noted.

Cattle Response

• Vaccination Protocol: Groups of 8 seronegative 6-month-old calves were immunized with 2 ml of vaccine delivered subcutaneously in the neck. A control group that received only the adjuvant was included (Potter et al., 2004).
• Persistence: Not noted.
• Immune Response: The group that received the vaccine showed a 13-fold increase in specific antibody titre to type III secreted proteins after a single immunization, and after a booster vaccination, the group demonstrated a 45-fold increase in specific antibody titre (Potter et al., 2004; Potter et al., 2004)
• Challenge Protocol: Animals were challenged two weeks following the final vaccination with 10^8 CFU of E. coli O157-H7 by oral-gastic intubation (Potter et al., 2004).
• Efficacy: On each of the post-challenge days, fewer vaccinated animals shed bacteria compared to the placebo group (Potter et al., 2004).